How Adaptive Designs can be used to compliment your clinical trial studies
SMI is proud to present the 6th annual conference…
/EINPresswire.com/ Adaptive Designs in Clinical Drug Development
'Buying in' to adaptive design trials: strategies and methods for implementing successful adaptive design studies
Monday 26th & Tuesday 27th March 2012, Grange Holborn, London
SMi proudly presents its Adaptive Designs in Clinical Drug Development, to be held on 26 & 27 March 2012 in London. This conference will address and explore key issues such as current technologies, dose finding, adaptive clinical trials for rare disease medicine development, Bayesian adaptive designs, high-density biomarker data and adaptive designs versus conventional trials. Learn how to maximise efficiency and profitability from case study examples and expert presentations.
This year, the conference will not only tackle issues surrounding effective management of your adaptive design in clinical trials but the increasing use of Bayesian modelling and using adaptive designs in early clinical trials. As adaptive designs are recently gradually evolving from a novel idea into a standard norm in the pharmaceuticals industry, industry leaders are asking themselves whether to adapt or not to adapt.
6 Reasons to attend Adaptive Designs in Clinical Drug Development;
• Learn how to maximise the benefits of an adaptive design through effective management
• Develop your knowledge of the adaptive designs. From start to end, it is important to know everything about adaptive clinical trials to gain maximum advantage.
• Understand the challenges of the high-density biomarker adaptive trial.
• Discover what the future holds in this rapidly evolving market and the impact of new regulation and technology.
• Improve your clinical trials in early phases to reduce costs and time.
• Evolve your understanding of current technologies to protect trial integrity, reduce operational bias and build regulatory confidence.
Our Key Speakers Include:
• Graeme Archer, Director, Quantitative Sciences - Clinical Statistics, GlaxoSmithKline
• Robert Clay, Vice President Regulatory Affairs, Oncology and Infection, AstraZeneca
• Sandrine Micallef , Clinical Biostatistics Oncology Sanofi-Aventis
• Giacomo Mordenti, Senior Expert Biostatistician Merck Serono
• Markus Niggli, Project Statistician & Annette Sauter, Project Statistician, Roche
• Prof Christopher Jennison, Professor of Statistics University of Bath
Alternatively or contact Fateja Begum on: +44 (0) 207 827 6184 e-mail: fbegum@smi-online.co.uk
http://www.smi-online.co.uk/2012adaptivedesigns21.asp
Quote "EIN News" & save £100
/EINPresswire.com/ Adaptive Designs in Clinical Drug Development
'Buying in' to adaptive design trials: strategies and methods for implementing successful adaptive design studies
Monday 26th & Tuesday 27th March 2012, Grange Holborn, London
SMi proudly presents its Adaptive Designs in Clinical Drug Development, to be held on 26 & 27 March 2012 in London. This conference will address and explore key issues such as current technologies, dose finding, adaptive clinical trials for rare disease medicine development, Bayesian adaptive designs, high-density biomarker data and adaptive designs versus conventional trials. Learn how to maximise efficiency and profitability from case study examples and expert presentations.
This year, the conference will not only tackle issues surrounding effective management of your adaptive design in clinical trials but the increasing use of Bayesian modelling and using adaptive designs in early clinical trials. As adaptive designs are recently gradually evolving from a novel idea into a standard norm in the pharmaceuticals industry, industry leaders are asking themselves whether to adapt or not to adapt.
6 Reasons to attend Adaptive Designs in Clinical Drug Development;
• Learn how to maximise the benefits of an adaptive design through effective management
• Develop your knowledge of the adaptive designs. From start to end, it is important to know everything about adaptive clinical trials to gain maximum advantage.
• Understand the challenges of the high-density biomarker adaptive trial.
• Discover what the future holds in this rapidly evolving market and the impact of new regulation and technology.
• Improve your clinical trials in early phases to reduce costs and time.
• Evolve your understanding of current technologies to protect trial integrity, reduce operational bias and build regulatory confidence.
Our Key Speakers Include:
• Graeme Archer, Director, Quantitative Sciences - Clinical Statistics, GlaxoSmithKline
• Robert Clay, Vice President Regulatory Affairs, Oncology and Infection, AstraZeneca
• Sandrine Micallef , Clinical Biostatistics Oncology Sanofi-Aventis
• Giacomo Mordenti, Senior Expert Biostatistician Merck Serono
• Markus Niggli, Project Statistician & Annette Sauter, Project Statistician, Roche
• Prof Christopher Jennison, Professor of Statistics University of Bath
Alternatively or contact Fateja Begum on: +44 (0) 207 827 6184 e-mail: fbegum@smi-online.co.uk
http://www.smi-online.co.uk/2012adaptivedesigns21.asp
Quote "EIN News" & save £100
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.